Summit Trail Advisors’s Cytokinetics CYTK Stock Holding History

Summit Trail Advisors’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-5,388	Closed	-$342K	–	1457
2025 Q4	$342K	Sell	5,388 -376	-7%	-$23.4K	0.01%	1184
2025 Q3	$317K	Sell	5,764 -991	-15%	-$40.8K	﹤0.01%	1198
2025 Q2	$223K	Buy	+6,755	New	+$235K	﹤0.01%	1028
2018 Q3	–	Sell	-1,770	Closed	-$15K	–	321
2018 Q2	$15K	Buy	+1,770	New	+$14.7K	0.01%	409
2018 Q1	–	Sell	-1,680	Closed	-$16K	–	731
2017 Q4	$16K	Buy	+1,680	New	+$19.1K	﹤0.01%	1095

Other funds holding CYTK

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Summit Trail Advisors's CYTK Position: Q1 2026 in Review

Summit Trail Advisors sold out of Cytokinetics (CYTK) in Q1 2026, closing a stake of 5,388 shares — an estimated $342K sold.

Summit Trail Advisors first reported a position in CYTK in Q4 2017 and held it in 5 quarters. The position peaked at $342K in Q4 2025. 439 funds tracked by Wall St. Rank hold CYTK as of Q1 2026.

Summit Trail Advisors reported no remaining Cytokinetics position as of Q1 2026 after selling out during the quarter.
Summit Trail Advisors sold 5,388 Cytokinetics shares in Q1 2026, an estimated $342K.
Summit Trail Advisors first reported a position in Cytokinetics in Q4 2017 and held it in 5 quarters.
Summit Trail Advisors's Cytokinetics position peaked at $342K in Q4 2025.
439 funds tracked by Wall St. Rank held Cytokinetics as of Q1 2026.

Based on Summit Trail Advisors's 13F filing for Q1 2026, filed 12 May 2026.